Goal-directed treatment of osteoporosis

Journal of Bone and Mineral Research

Volumn 28, Issue 3, 2013, Pages 433-438

  Cummings, Steven R ^a   Cosman, Felicia ^b,c   Eastell, Richard ^d   Reid, Ian R ^e   Mehta, Mona ^a   Lewiecki, E Michael ^f  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HELEN HAYES HOSPITAL   (United States)

^c College of Physicians and Surgeons ^*  (United States)

^d UNIVERSITY OF SHEFFIELD   (United Kingdom)

^e UNIVERSITY OF AUCKLAND   (New Zealand)

^f UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; DENOSUMAB; PARATHYROID HORMONE[1-34]; RALOXIFENE; RISEDRONIC ACID; ZOLEDRONIC ACID;

BONE DENSITY; BONE TURNOVER; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMUR NECK; FOLLOW UP; FRACTURE; HUMAN; MEDICAL DECISION MAKING; OSTEOPOROSIS; PRACTICE GUIDELINE; REVIEW; RISK ASSESSMENT; TREATMENT RESPONSE;

BONE DENSITY; FRACTURES, BONE; HUMANS; OSTEOPOROSIS;

EID: 84873963688     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.1854     Document Type: Review

References (25)

1. Diez-Perez A, Adachi JD, Agnusdei D, Bilezikian JP, Compston JE, Cummings SR, Eastell R, Eriksen EF, Gonzalez-Macias J, Liberman UA, Wahl DA, Seeman E, Kanis JA, Cooper C., Treatment failure in osteoporosis. Osteoporos Int. 2012; 23: 2769-74.
2. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jr., Jones DW, Materson BJ, Oparil S, Wright JT, Jr., Roccella EJ., Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003; 42: 1206-52.
3. Hackam DG, Khan NA, Hemmelgarn BR, Rabkin SW, Touyz RM, Campbell NR, Padwal R, Campbell TS, Lindsay MP, Hill MD, Quinn RR, Mahon JL, Herman RJ, Schiffrin EL, Ruzicka M, Larochelle P, Feldman RD, Lebel M, Poirier L, Arnold JM, Moe GW, Howlett JG, Trudeau L, Bacon SL, Petrella RJ, Milot A, Stone JA, Drouin D, Boulanger JM, Sharma M, Hamet P, Fodor G, Dresser GK, Carruthers SG, Pylypchuk G, Burgess ED, Burns KD, Vallee M, Prasad GV, Gilbert RE, Leiter LA, Jones C, Ogilvie RI, Woo V, McFarlane PA, Hegele RA, Tobe SW., The 2010 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2-therapy. Can J Cardiol. 2010; 26: 249-58.
4. Vasikaran S, Eastell R, Bruyere O, Foldes AJ, Garnero P, Griesmacher A, McClung M, Morris HA, Silverman S, Trenti T, Wahl DA, Cooper C, Kanis JA., Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int. 2011; 22: 391-420.
5. Civitelli R, Armamento-Villareal R, Napoli N., Bone turnover markers: understanding their value in clinical trials and clinical practice. Ost Int. 2009; 20: 843-51.
6. Mackey D, Black D, Bauer DC, McCloskey EV, Eastell R, Mesenbrink P, Thompson JR, Cummings SR., Effects of antiresorptive treatment on nonvertebral fracture outcomes. J Bone Miner Res. 2011; 26: 2411-8.
7. Leslie W, Lix L, Johansson H, Oden A, McCloskey E, Kanis JA., Does osteoporosis therapy invalidate FRAX for fracture prediction?. J Bone Miner Res. 2012; 27: 1243-51.
8. Lindsay R, Silverman SL, Cooper C, Hanley DA, Barton I, Broy SB, Licata A, Benhamou L, Geusens P, Flowers K, Stracke H, Seeman E., Risk of new vertebral fracture in the year following a fracture. JAMA. 2001; 285: 320-3.
9. Ryg J, Reinmark L, Overgaaard S, Brixen K, Vestergaard P., Hip fracture patients at risk of second hip fracture: a nationwide population-based cohort study of 169,145 cases during 1977-2001. JBMR. 2009; 24: 1299-307.
10. Hochberg M, Ross P, Black D, Cummings SR, Genant HK, Nevitt MC, Barrett-Connor E, Musliner T, Thompson D., Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Fracture Intervention Trial Research Group. Arthritis Rheum. 1999; 42: 1246-54.
11. Chapurlat RD, Palermo L, Ramsay P, Cummings SR., Risk of fracture among women who lose bone density during treatment with alendronate. The Fracture Intervention Trial. Osteoporos Int. 2005; 16: 842-8.
12. Schwartz A, Bauer D, Cummings SR, Cauley JA, Ensrud KE, Palermo L, Wallace RB, Hochberg MC, Feldstein AC, Lombardi A, Black DM., Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: The FLEX trial. J Bone Miner Res. 2010; 25: 976-82.
13. Cosman F, Cauley J, Boonen S, Palermo L, Reid I, Cummings SR, Black D., Who is at highest risk for new vertebral fractures after 3 years of annual zoledronic acid and who should remain on treatment? Presented at: ASBMR 2011 Annual Meeting; September 16-20, 2011; San Diego, CA.
14. Gourlay M, Fine J, Preisser JS, May RC, Li C, Lui LY, Ransohoff DF, Cauley JA, Ensrud KE., Bone-density testing interval and transition to osteoporosis in older women. N Engl J Med. 2012; 366: 225-33.
15. Lewiecki M, Binkley N., Bone density testing intervals and common sense. Curr Ost Rep. 2012; 10: 217-20.
16. Cummings S, Karpt D, Harris F, Genant HK, Ensrud K, LaCroix AZ, Black DM., Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med. 2002; 112: 281-9.
17. Sarkar S, Mitlak B, Wong M, Stock JL, Black DM, Harper KD., Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J Bone Miner Res. 2002; 17: 1-10.
18. Watts N, Geusens P, Barton IP, Felsenberg D., Relationship between changes in BMD and nonvertebral fracture incidence associated with risedronate: reduction in risk of nonvertebral fracture is not related to change in BMD. J Bone Miner Res. 2005; 20: 2097-104.
19. Austin M, Yang Y, Vittinghoff E, Adami S, Boonen S, Bauer DC, Bianchi G, Bolognese MA, Christiansen C, Eastell R, Grauer A, Hawkins F, Kendler DL, Oliveri B, McClung MR, Reid IR, Siris ES, Zanchetta J, Zerbini CA, Libanati C, Cummings SR., Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures. J Bone Miner Res. 2011; 27: 687-93.
20. Jacques R, Boonen S, Cosman F, Reid IR, Bauer DC, Black DM, Eastell R., Relationship of changes in total hip bone mineral density to vertebral and nonvertebral fracture risk in women with postmenopausal osteoporosis treated with once-yearly zoledronic acid 5 mg: The HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res. 2012; 12: 1627-34.
21. Lenchik L, Leib E, Hamdy R, Binkley NC, Miller PD, Watts NB., Executive Summary, International Society for Clinical Densitometry Position Development Conference, Denver, Colorado, July 20-21, 2001. J Clin Dens. 2002; 5 (Suppl): S1-3.
22. Lenchik L, Kiebzak G, Blunt B., What is the role of serial bone mineral density measurements in patient management?. J Clin Dens. 2002; 5 (Suppl): S29-38.
23. Writing Group for the ISCD Position Development Conference. Technical standardization for dual-energy X-ray absorptiometry. J Clin Dens. 2004; 7: 27-36.
24. Bonnick S, Shulman L., Monitoring osteoporosis therapy: bone mineral density, bone turnover markers, or both?. Am J Med. 2006; 119: 255-315.
25. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002; 106: 3143-21.